中再集團(1508.HK)領導一行拜訪國藥集團
7月21日，中再集團黨委書記、董事長袁臨江，黨委副書記、總裁和春雷一行，拜訪中國醫藥集團有限公司(下稱“國藥集團”)，並與國藥集團黨委書記、董事長劉敬楨等進行了深入會談。
劉敬楨董事長介紹了國藥集團產業經營業績、發展戰略及在舉國及全球對抗新冠疫情中所發揮的重要作用。他表示，今年國藥集團上半年的營業收入、淨利潤均創歷史新高，在中央企業中名列前茅，用良好的成績為建黨百年獻禮，也為“十四五”開了好局；“十四五”期間是國藥集團實施“四梁八柱、百強萬億”創新驅動型全生命週期、全產業鏈、全生態圈總體發展戰略的重要機遇，將深入發展四大核心主業、六大支柱產業及八大支撐平台經濟，中再集團擁有完整保險產業鏈，技術創新能力顯著，國藥集團願與中再集團攜手共進，構建並深化全面戰略合作關係，不斷拓寬合作範圍，共同服務國計民生，推進健康中國戰略。
袁臨江董事長祝賀國藥集團在戰“疫”大考中彰顯責任擔當，為保障人民生命健康發揮了不可替代的作用。他簡要介紹了中再集團的歷史沿革、發展近況及聚焦“平台化、科技化、全球化”戰略支點，服務國家戰略、創新發展、戰略佈局等方面取得的主要成績。他表示，醫藥和健康關乎國計民生，也是中再集團“十四五”戰略中的重要內容，雙方同為央企和行業“國家隊”，強強聯合，深化合作，共同落實健康中國戰略，服務國家“一帶一路”建設。和春雷總裁肯定了雙方的現有合作，並展望了未來合作的廣闊前景，表示中再集團將充分發揮自身優勢，在“一帶一路”建設、保險數據資源共享、產品創新與研發、再保、直保、經紀和投融資等領域開展全方位合作，為國藥集團高質量發展提供優質金融服務。
雙方就建立戰略合作伙伴關係達成共識，表示將統籌各自系統資源和優勢，建立多層次的合作，實現優勢互補，互利共贏。
國藥集團總會計師楊珊華，國藥控股、國藥國際、國藥投資、集團公司國際合作部、集團公司公共事務部，以及中再產險、中再壽險、中國大地保險、中再資產、華泰保險經紀、集團公司戰略發展部、集團公司戰略客户部等相關負責人蔘加了會談。
來源：中國再保險官微
原標題：中再集團領導一行拜訪中國醫藥集團有限公司
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
